Agenus Inc. (AGEN) earnings
AGEN earnings moved a median of -1.94% by the close. Quarterly and annual AGEN reports and results, each read against the price at its own news timestamp. Back to the AGEN overview →
29 measured AGEN earnings events.
Where these AGEN earnings landedvs 27 measured AGEN earnings reactions
| Middle 50% of AGEN earnings reactions | -3.96% to +2.80% |
|---|---|
| Median reaction (to close) | -1.94% |
| Measured reactions | 27 |
Point-in-time · zero look-ahead
Half of the 27 AGEN earnings events with a measured close landed between -3.96% and +2.80%; 41% closed up.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Form 10-Q AGENUS INC For: Jun 30 | SEC filing · Form 10-Q | -3.66% | — | |
| Agenus Reports Second Quarter 2026 Results and Advances Phase 3 ROBBIN Trial of BOT+BAL in Neoadjuvant MSS Colon Cancer | Press release | +4.49% | -2.35% | |
| Agenus to Provide Second Quarter 2026 Financial Report and Development Update | Press release | +3.33% | +0.46% | |
| Agenus Reports First Quarter 2026 Financial Results and Highlights BOT+BAL Execution Across Global Access and Phase 3 Development | Press release | -7.90% | -11.17% | |
| Form 10-Q AGENUS INC For: Mar 31 | SEC filing · Form 10-Q | +1.23% | +5.85% | |
| Agenus to Provide First Quarter 2026 Financial Report and Corporate Update | Press release | +1.26% | +2.71% | |
| Form 10-K AGENUS INC For: Dec 31 | SEC filing · Form 10-K | +1.80% | +19.46% | |
| Agenus Reports Q3 2025 Results Showcasing Clinical and Regulatory Advances | Press release | +6.53% | +5.78% | |
| Form 10-Q AGENUS INC For: Sep 30 | SEC filing · Form 10-Q | +2.39% | +2.15% | |
| Agenus to Provide Corporate Update and Third Quarter 2025 Financial Report | Press release | -0.27% | -2.12% | |
| Agenus Announces Second Quarter 2025 Financial Results and Virtual Meeting to Discuss Strategic Progress | Press release | -6.11% | -3.39% | |
| Form 10-Q AGENUS INC For: Jun 30 | SEC filing · Form 10-Q | -1.19% | — | |
| Agenus to Provide Corporate Update and Second Quarter 2025 Financial Report | Press release | -0.68% | -6.28% | |
| Form 10-Q AGENUS INC For: Mar 31 | SEC filing · Form 10-Q | +2.26% | -4.52% | |
| Agenus to Provide Corporate Update and First Quarter 2025 Financial Report | Press release | -5.96% | -4.39% | |
| Form 10-K AGENUS INC For: Dec 31 | SEC filing · Form 10-K | -2.89% | +0.00% | |
| Agenus Reports Third Quarter 2024 Financial Results and Strategic Advancements in BOT/BAL Development | Press release | +3.14% | -13.75% | |
| Form 10-Q AGENUS INC For: Sep 30 | SEC filing · Form 10-Q | +3.56% | -1.94% | |
| Agenus to Provide Third Quarter 2024 Financial Report and Corporate Update | Press release | +0.49% | +1.22% | |
| Agenus Reports Second Quarter 2024 Operational and Financial Results | Press release | +3.71% | +3.13% | |
| Form 10-Q AGENUS INC For: Jun 30 | SEC filing · Form 10-Q | +0.04% | -1.36% | |
| Agenus to Provide Second Quarter 2024 Financial Report and Corporate Update | Press release | +2.83% | +9.15% | |
| Agenus Reports First Quarter 2024 Results | Press release | -9.32% | -3.53% | |
| Form 10-Q AGENUS INC For: Mar 31 | SEC filing · Form 10-Q | -9.32% | -3.53% | |
| Agenus to Provide First Quarter 2024 Financial Report and Corporate Update | Press release | +1.56% | +12.15% | |
| Form 10-K AGENUS INC For: Dec 31 | SEC filing · Form 10-K | -1.12% | -10.77% | |
| Form 10-Q AGENUS INC For: Sep 30 | SEC filing · Form 10-Q | +0.05% | -14.70% | |
| Agenus Reports Third Quarter 2023 Results | Press release | -1.45% | -2.60% | |
| Agenus to Provide Third Quarter 2023 Financial Report and Corporate Update | Press release | +2.06% | +2.88% |
Keep exploring
More AGEN: analyst actions → · SEC filings → · AGEN overview →
Other Healthcare names and their earnings
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| TRANSENTERIX (TRXC) | 884 | -0.71% | 39% |
| OncoSec Medical Incorporated (ONCS) | 878 | -0.49% | 39% |
| Genocea Biosciences, Inc. (GNCA) | 873 | -0.47% | 40% |
| La Jolla Pharmaceutical Company (LJPC) | 869 | -0.08% | 45% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not. These are each name’s all-news baseline, not its earnings — that is what the link opens.